Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;26(8):e177-e182.
doi: 10.1016/j.bbmt.2020.04.013. Epub 2020 May 11.

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza  1 , Caitrin Fretham  2 , Stephanie J Lee  3 , Mukta Arora  4 , Janet Brunner  5 , Saurabh Chhabra  6 , Steven Devine  2 , Mary Eapen  6 , Mehdi Hamadani  6 , Parameswaran Hari  6 , Marcelo C Pasquini  6 , Waleska Perez  5 , Rachel A Phelan  6 , Marcie L Riches  7 , J Douglas Rizzo  6 , Wael Saber  6 , Bronwen E Shaw  6 , Stephen R Spellman  2 , Patricia Steinert  5 , Daniel J Weisdorf  5 , Mary M Horowitz  6
Affiliations
Review

Current Use of and Trends in Hematopoietic Cell Transplantation in the United States

Anita D'Souza et al. Biol Blood Marrow Transplant. 2020 Aug.

Erratum in

Abstract

Hematopoietic cell transplantation (HCT) is a well-established treatment to control and/or cure many malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. We report information about HCT procedures performed in the United States in 2018 and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall, compared with 2017, the number of allogeneic HCTs performed in the United States increased by 1%, and the number of autologous HCTs decreased by 5%. Key findings are fewer autologous HCTs performed for non-Hodgkin lymphoma and increasing numbers of haploidentical HCTs, nearly all of which use post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis. There is a continuing increase in HCT in adults age >70 years, particularly for acute myelogenous leukemia and myelodysplastic syndromes. Survival rates by disease, disease stage, donor type, and age are presented. This report, prepared annually by the CIBMTR, provides a snapshot of current transplant activity in the United States.

Keywords: Activity; Hematopoietic cell transplantation; Summary slides.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Annual Number of HCT Recipients in the US by Transplant Type
Figure 2a.
Figure 2a.
Indications for HCT in the US, 2018 (Adult)
Figure 2b.
Figure 2b.
Indications for HCT in the US, 2018 (Pediatric)
Figure 3.
Figure 3.
Myeloma and DLBCL Trends for Autologous HCT in the US
Figure 4a.
Figure 4a.
Trends in Autologous HCT in the US by Recipient Age^ ^Transplants for NHL, Hodgkin Disease and Multiple Myeloma
Figure 4b.
Figure 4b.
Trends in Allogeneic HCT in the US by Recipient Age^^ ^^Transplants for AML, ALL, MDS, NHL, Hodgkin Disease, Multiple Myeloma
Figure 5.
Figure 5.
Allogeneic HCT Recipients in the US, by Donor Type
See this image and copyright information in PMC

Comment in

  • Improving the Odds.
    Byrne M, Savani B, Copelan E. Byrne M, et al. Biol Blood Marrow Transplant. 2020 Aug;26(8):e173-e174. doi: 10.1016/j.bbmt.2020.04.017. Epub 2020 May 15. Biol Blood Marrow Transplant. 2020. PMID: 32417492 No abstract available.

References

    1. Kanate AS, Majhail NS, Savani BN, et al. : Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy: Guidelines for Hematopoietic Transplantation and Cellular Therapy. Biol Blood Marrow Transplant, 2020 - PubMed
    1. https://www.cancer.gov/news-events/cancer-currents-blog/2018/tisagenlecl..., 2018
    1. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-appro..., 2017
    1. Jain T, Bar M, Kansagra AJ, et al. : Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25:2305–2321, 2019 - PubMed
    1. Muffly L, Pasquini MC, Martens M, et al. : Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood 130:1156–1164, 2017 - PMC - PubMed

Publication types

Substances